Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : iqDNA
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA and is investigated for hemop...
Brand Name : Immune-quiet DNA
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 18, 2023
Lead Product(s) : iqDNA
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Genetic Medicine
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Moderna Therapeutics
Deal Size : $76.0 million
Deal Type : Collaboration
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Details : The collaboration will combine Moderna’s expertise with Generation Bio’s non-viral genetic medicine platform to develop novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate pipelines of non-viral genetic me...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $40.0 million
March 23, 2023
Lead Product(s) : Genetic Medicine
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Moderna Therapeutics
Deal Size : $76.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program
Details : Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in mice.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
December 14, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Closed-ended DNA
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) to address inherited retinal diseases with full gene replacement.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 22, 2021
Lead Product(s) : Closed-ended DNA
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
Details : Generation Bio shared preclinical data demonstrating broad access to key cell types with our lipid nanoparticle developed for the retinal disease with utilization of non-viral genetic medicine platform incorporates a novel DNA construct called closed-end...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human monoclonal antibodies
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The companies believe that this technology, coupled with Vir’s potent neutralizing antibodies, has the potential to provide effective, long-lasting protection against SARS-CoV-2.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 30, 2020
Lead Product(s) : Human monoclonal antibodies
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?